Owen Capocyan, MD
Geriatric Medicine · Sugar Land, TXNPI 1063695328
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 52 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by SK Life Science, Inc. at 26.6% of the total. Reporting peaked in 2024 at $386 and has fallen 80.3% since, to $76 in 2025.
Across 52 payments — averaging $28.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SK Life Science, Inc.$393
- Amgen$272
- AstraZeneca$137
- Astellas Pharma US Inc$125
- Teva Pharmaceuticals USA, Inc.$103
- Aimmune Therapeutics, Inc.$73
- plus $374 from 16 others
What the payments were for
- Food & beverage$1,476100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| SK Life Science, Inc. | 13 | $393 |
| Amgen(2 entities) | 4 | $272 |
| AstraZeneca | 2 | $137 |
| Astellas Pharma US Inc | 7 | $125 |
| Teva Pharmaceuticals USA, Inc. | 1 | $103 |
| Aimmune Therapeutics, Inc. | 3 | $73 |
| Johnson & Johnson | 4 | $64 |
| Lundbeck LLC | 2 | $42 |
| Nestle Healthcare Nutrition Inc. | 2 | $39 |
| AbbVie | 2 | $26 |
| Lilly USA, LLC | 1 | $21 |
| Eisai Inc. | 1 | $21 |
| Hologic Sales And Service, LLC | 1 | $18 |
| Mylan Pharmaceuticals Inc. | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Pfizer | 1 | $17 |
| Acadia Pharmaceuticals Inc | 1 | $17 |
| Exact Sciences | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Novartis | 1 | $14 |
| Vivus LLC | 1 | $14 |
| Novo Nordisk | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,476 in reported general payments places this provider in the 80th percentile of 275 geriatric medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 492 | $157,459 |
| AptiomEslicarbazepine Acetate | 106 | $66,834 |
| JardianceEmpagliflozin | 156 | $60,285 |
| OzempicSemaglutide | 56 | $58,133 |
| JanuviaSitagliptin Phosphate | 132 | $51,995 |
| ZenpepLipase/Protease/Amylase | 26 | $43,410 |
| Invega SustennaPaliperidone Palmitate | 14 | $43,148 |
| XifaxanRifaximin | 26 | $42,299 |
| XareltoRivaroxaban | 83 | $31,647 |
| NuplazidPimavanserin Tartrate | 21 | $28,860 |
| FarxigaDapagliflozin Propanediol | 71 | $28,712 |
| GemtesaVibegron | 102 | $25,787 |
| Chlorpromazine Hcl | 49 | $17,792 |
| TrulicityDulaglutide | 18 | $15,545 |
| Memantine Hcl | 343 | $12,842 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $17 | $157,459492 claims |
| Johnson & JohnsonInvega Sustenna, Xarelto | $64 | $74,79597 claims |
| Novo NordiskOzempic | $13 | $58,13356 claims |
| Aimmune Therapeutics, Inc.Zenpep | $73 | $43,41026 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $137 | $40,625132 claims |
| Acadia Pharmaceuticals IncNuplazid | $17 | $28,86021 claims |
| Lilly USA, LLCTrulicity | $21 | $15,54518 claims |
| AbbVieLinzess | $26 | $10,88319 claims |
| AmgenAranesp | $272 | $4,95111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 275 geriatric medicine providers in Texas.
Other geriatric medicine in Sugar Land
- Ranganath KandalaSugar Land$5K
- Arusha BavareSugar Land$2K
- Mauricio Gonzalez-AriasAustin$825K
- Eberenne IgbokwePearland$124K
- Diana KerwinDallas$81K
- David SmithBrownwood$19K
- Alejandro ArizmendiHelotes$15K
- Rosa VizcarraSan Antonio$9K
- George TaffetHouston$9K
- John CarrollCorpus Christi$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.